What to expect,
week by week.

A steep on-ramp. Most people feel the drug within days — appetite drops hard, GI side-effects arrive early, and the body slowly adapts over the first month before the smoother 'quiet' phase sets in.

Gentler on-ramp than retatrutide but a similar shape. Appetite suppression is strong, GI side-effects front-load, and the sweet spot is often found around 5–7.5 mg before diminishing returns.

The slowest and gentlest of the GLP-1 family. Effects build over weeks, not days. Patience pays off — people who quit at week 4 for 'not working' usually stopped just before the curve steepens.

Subtle and slow. Rarely produces a 'felt' effect. Improvements usually surface as an injury quietly stops hurting, not a sudden shift.

Long half-life means slow, cumulative feel. Often stacked with BPC-157 for injury recovery. The first cycle is where responders self-identify.

Cosmetic and repair effects build over months. Injectable users report systemic feel; topical users see skin and hair changes.

The gentle secretagogue. Pulses growth hormone without the hunger or cortisol spikes of stronger ghrelin mimetics. Effects are felt in sleep quality first, body composition later.

The long-half-life partner to ipamorelin. Instead of daily pulses it creates a sustained GH 'bleed'. Effects are steadier but blunter than pulsatile stacks.

Oral, potent, and hunger-forward. Sleep improves fast but so does appetite — many users gain fat if they don't restrain intake.

The visceral-fat specialist. Slower to show than GLP-1s but targets a fat depot they don't touch. Effects are measured in months.

The oldest and gentlest GHRH. Slow, physiologic. Better suited to long-term wellness use than short 'transformation' cycles.